STAT News

DECEMBER 1, 2022

We cover all these topics and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast. The first FDA-approved fecal microbiome drug. And a stinging defeat for Big Pharma’s lobbying arm.

FDA Approval 94

FDA Approval Drugs Research 94

Velocity Clinical Research

JUNE 7, 2023

Paul Evans, PhD, President and Chief Executive Officer of Velocity, has been named a featured speaker of the Biotech and Pharmaceutical Management Summit through Cornell University. We look forward to engaging with other industry leaders and Cornell faculty to drive meaningful conversations and shape a better future for clinical research.

Clinical Research 52

Clinical Research Clinical Trials Clinical Trials Trials 52

WCG Clinical

MAY 25, 2023

Related Topics Clinical Trial Operational Excellence Clinical Endpoint Solutions Videos Most Recent Posts Why Biotech Sponsors Need Outside Support: IRB, IBC, DMCs and EACs More Guidance, Less Variability: Digital EDSS Givers Raters a More Precise, More User-Friendly Tool for MS Assessments Improving Research Billing Outcomes: The Real Impact of Coverage (..)

Clinical Trials 52

Clinical Trials Clinical Trials Trials Research 52

XTalks

MAY 26, 2023

Krystal Biotech’s Vyjuvek has been awarded US Food and Drug Administration (FDA) approval to make it the first topical gene therapy for the treatment of wounds in patients with the rare, often debilitating skin disease dystrophic epidermolysis bullosa (DEB). As a topical treatment, it is also the first readily redosable gene therapy.

Gene Therapy 97

Gene Therapy Gene FDA Approval Dermatology 97

XTalks

JANUARY 2, 2024

Chiesi Global Rare Diseases, a specialized division within the Chiesi Group dedicated to pioneering therapies for individuals affected by rare diseases, has received approval from the US Food and Drug Administration (FDA) for Filsuvez (birch triterpenes) topical gel. percent of cases.

FDA Approval 111

FDA Approval Gene Therapy Gene Trials 111

Pharmaceutical Technology

APRIL 3, 2023

Sartorius , through its French listed sub-group Sartorius Stedim Biotech , has signed an agreement to acquire Polyplus for €2.4bn ($2.6bn). Topic sponsors are not involved in the creation of editorial content. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 246

Gene Therapy Gene DNA Reagent 246

Pharmaceutical Technology

SEPTEMBER 21, 2022

Topic sponsors are not involved in the creation of editorial content. The post Rocket agrees to acquire biotech firm Renovacor appeared first on Pharmaceutical Technology. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 147

Gene Therapy Gene Cardiology Genetics 147

BioTech 365

APRIL 22, 2021

Active Biotech AB Interim report January – March 2021 Active Biotech AB Interim report January – March 2021 Financing completed and good progress in the projects First quarter in brief Agreement signed for manufacturing of a topical ophthalmic formulation and capsules of … Continue reading →

Manufacturing 40

Manufacturing 40

XTalks

NOVEMBER 15, 2023

In the dynamic and ever-evolving landscape of biotechnology, industry leaders must stay informed of biotech trends and garner industry insights for 2024 and beyond. At the cutting edge of medical innovation, these biotech companies encounter various challenges that test their resilience, creativity and adaptability.

Marketing 64

Marketing Production Trials Clinical Trials 64

ACRP blog

FEBRUARY 28, 2024

A biotech company CEO for disseminating misleading information about the efficacy of a particular drug (DOJ: “Former InterMune CEO Sentenced for False & Misleading Statements Related to Pulmonary Fibrosis Drug’s Clinical Tests”) A New York researcher who misused grant funds for personal travel and entertainment purposes ( United States ex rel.

Compliance 59

Compliance Research Clinical Research Clinical Trials 59

Drug Discovery World

OCTOBER 31, 2022

Collaborative Drug Discovery (CDD) is hosting a webinar in which CDD’s Eric Gifford speaks with two industry experts, Dr Josh Horan and Dr Michael Kappler about their experience working with data at biotech companies. . Discussion topics will include: . Which technologies the panelists use in their informatics workflow and why .

Drugs 52

Drugs Medicine Research 52

BioTech 365

NOVEMBER 8, 2021

AlgoTherapeutix appoints Prof Jens Ellrich Chief Medical Officer AlgoTherapeutix appoints Prof Jens Ellrich Chief Medical Officer PARIS–(BUSINESS WIRE)–AlgoTherapeutix (AlgoTx) is a European Biotech developing ATX01, a non-opioid topical treatment for Peripheral Neuropathic Pain.

Development 52

Development 52

Delveinsight

SEPTEMBER 20, 2021

The Onychomycosis treatment market offers several options, including oral antifungals, topical antifungals, and devices. Three major Topical treatments are currently on the market with two of them being approved as late as 2014 by the US FDA. Thus, there is a dire need for proper diagnosis alongside treatment options.

Marketing 74

Marketing Cosmetics Drug Delivery Clinical Development 74

XTalks

MARCH 25, 2021

Each week, host Sydney Perelmutter will be joined by editorial team members, Mira Nabulsi, Ayesha Rashid and Sarah Hand to discuss trending food industry topics and share insights from industry experts. Sydney writes about various food industry topics, including safety and regulation, grocery and foodservice, innovation and sustainability.

Life Science 95

Life Science HR Branding Production 95

Pharmaceutical Technology

FEBRUARY 16, 2023

The University of Texas MD Anderson Cancer Center has entered a strategic collaboration with biotech company Xilis for advancing new technology and expediting new cancer therapy development. Topic sponsors are not involved in the creation of editorial content.

Development 242

Development Gene Therapy Gene Drugs 242

VirTrial

JANUARY 2, 2024

That’s why we launched Signant Biotech – an integrated clinical research approach leveraging software and services tailored to small- to mid-sized biopharmaceutical organizations’ unique needs as well as the CROs who support them.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

pharmaphorum

JUNE 4, 2021

The inaugural Prostate Cancer Drug Development Summit is the only industry-led meeting uniting large pharma, biotech and pioneering academics with the ambitious objective of accelerating the clinical development of safe and effective therapies to treat prostate cancer. Bringing theranostics to prostate cancer.

Development 98

Development Drugs Clinical Development 98

Drug Discovery World

JULY 27, 2023

Dr Alfonso Sabater, Associate Professor of Ophthalmology, Medical Director of Bascom Palmer’s Ocular Surface Program and Director of the Corneal Innovation Lab, approached manufacturer Krystal Biotech about creating a formulation of their gene therapy for the eyes.

Gene Therapy 52

Gene Therapy Gene Genetics Clinical Trials 52

Pharmaceutical Technology

JUNE 8, 2023

The companies will offer a comprehensive suite of cell therapy services to biotech, pharmaceutical and government entities, and to hospitals. Topic sponsors are not involved in the creation of editorial content. The core objective of the collaboration is to make the therapies affordable and accessible to patients.

Gene Therapy 130

Gene Therapy Gene Development Antibody 130

Drug Discovery World

MAY 8, 2023

UK company Tay Therapeutics has entered into an exclusive license agreement with US biotech VYNE Therapeutics for its oral bromodomain and extra-terminal domain (BET) inhibitor TAY-B2. Tay Therapeutics out-licensed its topical pan-BET inhibitor to VYNE for £16m in upfront and milestone payments in 2021.

Licensing 52

Licensing Licensing Sales Development 52

Worldwide Clinical Trials

FEBRUARY 26, 2024

Among the various topics discussed, here are a few highlights of the panelists’ conversation: Challenging Traditional Approaches As an industry, Perez points out that we tend to stick to what we are accustomed to in terms of protocol design and traditional clinical operations.

Clinical Trials 137

Clinical Trials Clinical Trials Trials Clinical Research 137

Drug Discovery World

DECEMBER 19, 2022

Researchers have found that a topical gene therapy gel helps heal wounds in patients with life-threatening blistering skin disease epidermolysis bullosa (EB). . The results of the trial, which was funded by Krystal Biotech, were published in The New England Journal of Medicine. Now he can bathe and sleep on his back without pain.

Gene Therapy 52

Gene Therapy Gene Dermatology Clinical Trials 52

Pharmaceutical Technology

MAY 17, 2023

At a lively panel at Financial Times US Pharma and Biotech Summit on May 16, panellists were at odds over whether the new legislation would improve treatment affordability or stifle pharma innovation. Insulin affordability has continued to prove a hot button topic as major pricing reforms are on the way.

Insulin 130

Insulin Drugs Pharma Companies Manufacturing 130

Pharmaceutical Technology

MAY 3, 2023

Janssen Biotech and the Cellular Biomedicine Group (CBMG) have entered a global collaboration and licence agreement for the development of next-generation chimeric antigen receptor (CAR) T-cell therapies to treat B-cell malignancies. Topic sponsors are not involved in the creation of editorial content.

Gene Therapy 147

Gene Therapy Sales Gene Development 147

Drug Discovery World

NOVEMBER 29, 2022

Topics covered . One of the key topics of the session was inspirational leaders – specifically, female leaders. Edwards said: “We went into those key topic areas and unpicked those, asking if it’s a strategy that they would use within their organisations.

Life Science 52

Life Science Drugs Development 52

Pharmaceutical Technology

DECEMBER 27, 2022

Drug pricing was a hot-button topic, and William Newton found that while e-commerce chains could cut insulin prices , any major change won’t happen overnight. You can sign up for newsletters to never miss the latest news on pharma and biotech, clinical trial strategy and operations , and medical devices. See you in 2023!

Clinical Trials 306

Clinical Trials Clinical Trials Trials Vaccination 306

Drug Discovery World

AUGUST 25, 2023

GDC : I’m Head of Research for a young, dynamic biotech called iOnctura. Whereas traditionally biotechs have studied the effect of a drug on a singular pathway, we are focused on targets that are involved in multiple independent tumour supressing pathways. MT: Where do you work, and can you tell us what you’re working on at the moment?

Research 98

Research Scientist Drugs Development 98

pharmaphorum

AUGUST 28, 2020

Italian biotech Cassiopea has won US approval for Winlevi, a topical therapy it says is the first new approach to treating acne in nearly 40 years. The biotech isn’t revealing how much it intends to charge for the new medicine, saying it will do so closer to launch later this year.

Dermatology 52

Dermatology Drugs Hormones FDA Approval 52

Pharmaceutical Technology

JANUARY 20, 2023

However, during the Covid-19 pandemic, the US-based biotech rose to prominence as it was one of the first companies to develop Covid-19 vaccines with its mRNA technology. On January 4, the company announced plans to acquire Japanese biotech OriCiro Genomics in an $85 million deal. In 2021, Moderna had a net income of $12.2

Manufacturing 246

Manufacturing Vaccination Vaccine Gene Therapy 246

Drug Discovery World

SEPTEMBER 2, 2022

He will cover My Green Labs Carbon Impact of the Biotech & Pharma study and how programmes are being utilised by labs in sectors including academia, pharma, biotech and wider, to run labs in a more sustainable way and green their supply chains. .

Drugs 52

Drugs Business Development Development Medicine 52

pharmaphorum

NOVEMBER 2, 2021

The approach has become a hot topic in biopharma with a string of big ticket partnerships over the last couple of years, including a $2.4 Alongside Novartis, BioGeneration Ventures (BGV) has also come onboard as a new investor, with general partner Oskar Slotboom joining the biotech’s board.

Protein 98

Protein Licensing Licensing Drugs 98

Drug Discovery World

OCTOBER 9, 2023

You will also hear from Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, on the topic ‘The benefits of AI in drug discovery’ Helen Liu-Mayo, Product Manager at Benchling, will answer the question: What is the true opportunity with ML and AI in biotech?

Drugs 52

Drugs Medicine Production Trials 52

Drug Discovery World

OCTOBER 3, 2023

You will also hear from Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine, on the topic ‘The benefits of AI in drug discovery’ Helen Liu-Mayo, Product Manager at Benchling, will answer the question: What is the true opportunity with ML and AI in biotech?

Drugs 52

Drugs Medicine Production Trials 52

Drug Discovery World

AUGUST 2, 2022

The seminars will include high profile speakers from pharma and biotech covering topics such as First Steps in Automation, Lab 4.0, DDW has been selected by ELRIG as the exclusive partner to organise and moderate the programme. . Data Handling and Choosing the Right Informatics System for your Lab plus much more. .

Drugs 52

Drugs Research 52

pharmaphorum

JANUARY 13, 2022

AstraZeneca has expanded its efforts to develop new therapies targeting transcription factors – proteins that regulate processes in the cell that have become a hot topic for drug discovery in cancer and other diseases. It’s not the big pharma’s first foray into the transcription factor area.

Protein 58

Protein Gene Expression Regulation Gene 58

Pharmaceutical Technology

JANUARY 11, 2023

AbbVie has collaborated with Anima Biotech for the discovery and development of mRNA biology modulators against three oncology and immunology targets. Topic sponsors are not involved in the creation of editorial content. AbbVie will get exclusive rights to license and develop and market the programmes. Free Whitepaper.

Gene Therapy 147

Gene Therapy Gene Development Licensing 147

pharmaphorum

OCTOBER 18, 2022

Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC) that has screened over 100 European biotechnology companies.

Clinical Trials 58

Clinical Trials Clinical Trials Production Development 58